Immunotherapy for Infectious Diseases

274 Sili, Heslop, and Rooney
73. van Driel WJ, Ressing ME, Brandt RM, et al. The current status of therapeutic HPV vaccine.
Ann Med 1996; 28:471–477.
74. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for
a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.
J Immunol 1992; 148:2617–2621.
75. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients
with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer
1999; 35:946–952.
76. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical
and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus
type 16 E7. Clin Cancer Res 1998; 4:2103–2109.
77. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding
human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical
cancer [see comments]. Lancet 1996; 347:1523–1527.
78. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity
induced in mice by HPV 16 L1 virus-like particles. Microbiol Pathogen 1997;
22:219–225.
79. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver
defined CTL epitopes to the MHC class I pathway. Virology 1998; 240:147–157.
80. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection.
Clin Microbiol Rev 1999; 12:351–366.
81. Waters JA, Foster GR, Thursz MR, Thomas HC. Hepatitis B virus infection and immunity.
In: McCance DJ (ed). Human Tumor Viruses. Washington, DC: ASM, 1998, pp. 283–299.
82. Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. Human histocompatibility
leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte
responses in patients with acute hepatitis. J Clin Invest 1997; 100:503–513.
83. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine
to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte
response in humans. J Clin Invest 1995; 95:341–349.